Biblio
Allogeneic Stem Cell Transplantation for patients with lower risk MDS. Biol Blood Marrow Transplant. 2020.
. Incidence and Outcome of Late Relapse after Allogeneic Stem Cell Transplantation for Myelofibrosis. Biol Blood Marrow Transplant. 2020.
. . Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
Allogeneic stem cell transplantation for myelofibrosis patients aged ≥ 65 years. Eur J Haematol. 2019.
. B cell maturation antigen-specific CAR T cells for relapsed or refractory multiple myeloma: a meta-analysis. Eur J Haematol. 2019.
. The Burden of Hepatitis E among Patients with Hematological Malignancies: a Retrospective European Cohort Study. J Hepatol. 2019.
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034-4042.
Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2018:JCO2018792184.
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374(1):43-53.
Outcome after transplantation according to reduced intensity conditioning regimen in patients transplanted for myelofibrosis. Biol Blood Marrow Transplant. 2016.
. International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the MAGIC consortium. Biol Blood Marrow Transplant. 2015.
Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines. Anticancer Res. 2014;34(4):1779-84.
.